The results will need to confirmed in a much bigger clinicaltrial, the designof which Acorda will need to discuss with the Food and Drug Administration.
For the best outcome and restoration of trust, this completely independent group of researchers would analyze data (and preferably design) from an industry-linked clinicaltrial.